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Abstract
Background: The quality of prenatal care is critical for the prevention of adverse pregnancy outcomes. However,
according to the World Health Organization (WHO), only 64 % of women worldwide have access to over four
sessions of prenatal care throughout their pregnancy. Thus, studies that address factors affecting maternal and child
health status before and after pregnancy are of immense importance. The primary aim of the mothers and their
children’s health (MATCH) cohort study is to evaluate the effect of nutrition, sleep quality, and lifestyle on maternal
and neonatal outcomes.
Methods: A prospective cohort of > 2500 pregnant women in the first trimester (before 12 weeks’ gestation) will
be recruited at Arash Women’s Hospital in Tehran, Iran between February 2020 and August 2021. All eligible
pregnant women will be followed from their first trimester of pregnancy until delivery at four time points and
assessed through a series of in-person visits with interviewer-administered questionnaires and telephone interviews.
Detailed data will be collected on maternal demographics, lifestyle, medical history, reproductive history, obstetric
history, dietary intake, sleep pattern, blood specimens, and anthropometric measurements, alongside paternal
demographics, lifestyle, and family history. The outcomes will include antenatal, peripartum, and postnatal maternal
complications and infant growth and neurodevelopment.
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Discussion: The results of the MATCH cohort study will support the development of contextual interventions that
can enhance antenatal, peripartum, and postnatal status, neonatal outcomes, and longevity mother and child.
Keywords: Life style, Maternal health, Maternal Nutritional physiological phenomena, Nutrition, Pregnancy,
Pregnancy Outcome, Prenatal care
Background
Pregnancy is a high-risk period for expectant mothers
and their unborn children and weighs significantly on
family and community health status, potentially affecting
the quality of life for future generations [1]. Unfortu-
nately, over 830 pregnant women die every day through-
out the world due to preventable adverse pregnancy
outcomes [2]. According to a 2015 WHO report, 303,
000 women died in 2015 due to pregnancy-related com-
plications, and an additional 2.7 million cases of neo-
natal death and 2.6 million cases of stillbirth are
reported annually. The maternal mortality ratio (MMR)
varies from 239 to 100,000 live births in developing
countries to 12 per 100,000 live births in developed
countries. Ninety-nine percent of maternal deaths have
been reported to occur in developing countries, with
higher incidences in rural areas and low-income com-
munities [3].
According to the 2015 WHO report, the major causes
of maternal mortality during pregnancy and childbirth
are preventable complications, including severe bleeding
(mainly postpartum hemorrhage), infection (usually
postpartum infections), hypertensive disorders, delivery
complications, and unsafe induced abortion. Other
causes are attributed to pre-existing disorders that have
worsened or initially appeared during pregnancy [3].
The quality of prenatal and postnatal care is critical for
the prevention of these complications, however only
64 % of women worldwide have access to over four ses-
sions of prenatal care [4]. Improvement of maternal
health is one of the essential priorities of the WHO with
a goal to decrease MMR to fewer than 70 deaths per
100,000 live births globally by 2030. To reach this goal,
the WHO works to implement clinical evidence-based
guidelines and programs, set global standards, and pro-
vide technical support to Member States [3]. Maternal
health has also been accepted as one of the United Na-
tions Millennium Development goals, furthering inter-
national support for decreasing maternal mortality [5].
Due to these benchmark maternal health goals, studies
addressing factors affecting maternal and child health
status before and after pregnancy are of utmost import-
ance, [6] and extensive new studies on adverse perinatal
outcomes are warranted as risk factors continue to
evolve [7, 8]. Evidence-based preventive and therapeutic
decision-making, particularly for pregnant women, has
become increasingly important in recent years due to
the irreversibility of adverse pregnancy outcomes [9, 10].
Limited access and inadequate intake of well-balanced
and nutrient-rich nutrition may affect maternal and
child health. Few studies have investigated the dietary in-
take of pregnant women in Iran. Previous research has
reported inadequate maternal energy and macronutrient
intake. Further, low levels of micronutrients, namely
iron, calcium, zinc, magnesium and copper, reported in
both mothers and neonates, which may be indicative of
the health status of women and neonates worldwide [11,
12]. The primary aim of the MATCH cohort study is to
evaluate the effect of nutrition, sleep quality, and lifestyle
on maternal and neonatal outcomes. The purpose of the
present article is to explain the study protocol and
methods used in this study.
Methods
Design overview
The MATCH cohort study will prospectively follow a
cohort of > 2500 pregnant women in Tehran, Iran. The
study will be conducted at the Arash Women’s Hospital
which is affiliated with Tehran University of Medical
Sciences. The Arash Women’s Hospital is one of the lar-
gest obstetrics and gynecology hospitals in Iran with ap-
proximately 2000 births per year. Enrollment of all
eligible pregnant women will be referred before 12
weeks of gestation through partnerships with prenatal
care providers. All eligible pregnant women will be
followed from their first trimester of pregnancy until de-
livery by a series of face-to-face visits with interviewer
administered questionnaires, anthropometric measure-
ments, biospecimen collections, and phone conversa-
tions at four time points.
This study has been approved by the Ethics Commit-
tee of Tehran University of Medical Sciences. The iden-
tity number is IR.TUMS.MEDICINE.REC.1398.576.
Before the study begins, written informed consent will
be obtained from participants. Due to the length of the
study, consent will be reobtained every six months.
Eligibility and enrollment
All pregnant women of Iranian nationality aged 18 to 45
in their first trimester will be included in the study. Pa-
tients will be enrolled from February 2020 through Au-
gust 2021. Exclusion criteria are the following: metabolic
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or chronic diseases, those following a special diet, the
use of certain food supplements (except for pregnancy
supplements, such as iron or folate) and physical, mental
or cognitive impairments which preclude participation
or informed consent.
The measurements and data collection time points
throughout the project are described in Table 1. There
are four data collection time points. Ten trained inter-
viewers will collect the data during the weekdays with
the exception of holidays).
Baseline data will be collected before the 12th week of
gestation and provide information on maternal demo-
graphics, lifestyle, medical, reproductive, obstetric, social
history, maternal nutritional status, and sleep patterns
for one year before the pregnancy. Further, paternal
demographics, social history, lifestyle, and family history
data will be collected. Additional data including blood
samples and anthropometric measurements will only be
collected at the first prenatal visit. Patients will be sur-
veyed a second time at 24 weeks of gestation (± 14 days).
The data collected at this second point will provide in-
formation about maternal physical activity and details of
maternal family history. Patients will be surveyed a third
time at the 32 weeks of gestation (± 14 days). The data
collected at this third point will include information
about sleeping disorders during the early stages of the
Table 1 description of data elements and timeline
















Maternal demographics × Standardized interview Standardized questions
Maternal lifestyle × Standardized interview Standardized questions
Maternal medical history × Standardized interview Standardized questions
Maternal reproductive
history
× Standardized interview Standardized questions
Maternal obstetric history × Standardized interview Standardized questions
Maternal family history × Standardized interview Standardized questions
Maternal dietary intake × Standardized interview Validated questionnaire (FFQ)
Maternal physical activity × Standardized interview Validated questionnaire (IPAQ)
Maternal sleep pattern × Standardized interview Validated questionnaire
(Pittsburgh Sleep Quality Index)
(Epworth Insomnia Severity Index)
Paternal demographics × Standardized interview Standardized questions
Paternal lifestyle × Standardized interview Standardized questions
Paternal medical history × Standardized interview Standardized questions
Paternal family history × Standardized interview Standardized questions




Digital weight scale (seca 813)
Digital height scale (seca 206)
Aneroid sphygmomanometer (seca b10)





Automated hematology analyzer (sysmex
corporation, kobe, Japan)




Baby weight scale (seca 376)
















Infant health × Standardized telephone
interview
Standardized questions
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pregnancy. The final data collection point will be com-
pleted between 12 and 72 h after delivery, and will in-
clude data on birth outcomes, including gestational age,
birth weight, and size, delivery type, and any intrapartum
or postpartum maternal and neonatal complications.
The study interviewers will maintain regular contact
with women via telephone, email or text message and be
notified if the participants give birth at another hospital.
Quality assurance and quality control procedures
For quality assurance and quality control, we will employ
proactive and thorough participant-tracking techniques.
During the first visit, contact information, including
home and work addresses, telephone numbers (home
and work), cell phone number for both the participant
and her husband, e-mail address and contact informa-
tion for next of kin and a close friend will be obtained.
During data collection, the quality of the data will be
checked weekly to identify interviewer bias. 10 % of the
data will be monitored and checked monthly by an inde-
pendent researcher to ensure completeness. In order to
ensure the reliability of the collected data, all inter-
viewers will be trained prior to the start of the study
using a variety of strategies, such as formal training ses-
sions, practical demonstrations and role-plays, to learn
how to explain the study objectives, take consent and
administer the questionnaire. A training handbook will
be used to ensure standardization of instructions and co-
herence of training norms for interviewers throughout
the project.
Socio‐economic, demographic and medical history
variables
In the first visit, socio-economic and demographic data
will be collected using a structured interview. Data will
include date of birth, educational level, employment sta-
tus, economic status based on home appliances [13],
number of members in the household, homeownership
status, and lifestyle variables, such as smoking, alcohol,
and drug addiction. Past medical and surgical histories,
alongside family history of diseases in first-degree rela-
tives will be assessed. Details will also be recorded about
reproductive history, including parity, gravidity, history
of stillbirth or spontaneous abortion, previous modes of
delivery, history of multiple births, family history of mul-
tiple births either in the participant’s family or her hus-
band’s family, and history of adverse pregnancy
outcomes, including pre-eclampsia, eclampsia, gesta-
tional diabetes, embryonic developmental disorder. In-
terviewers will also collect information related to
infertility history, including duration, cause, and type of
infertility, use of fertility treatments, and history of gam-
ete or embryo donation.
Nutrition: Food Frequency Questionnaire (FFQ)
Participants’ dietary intake will be evaluated during the
first visit using the 168-item FFQ that contains questions
about the type/brand of food, cooking methods, and fre-
quency and amount of all foods and drinks they con-
sumed during the one-year period leading up to the
pregnancy. The FFQ was validated for the population in
the Tehran Lipid and Glucose Study (TLGS), and its
relative validity and reproducibility was proven [14]. For
FFQ data, portion sizes will be converted to grams per
week per food item by two experienced nutritionists.
Maternal anthropometric measurements
Maternal height, waist circumference and hip circum-
ference will only be measured at the first visit, but
maternal weight will be measured at all four visits.
Each measurement will be carried out twice and the
mean will be recorded. If the second measurement is
greater than or less than the 1.5 % standard deviation
of the first measurement, a third measurement will be
made and the midpoint measurement will be re-
corded. Weight will be measured with a digital weight
scale (Seca 813) capable of weighing a maximum of
150 kg with an accuracy of 50 g. Before weighing,
participants will be asked to remove their shoes, extra
or heavy clothing, and empty their pockets. Infants
will be weighed without clothes using a baby scale
(Seca 376), with an accuracy of 10 g. Height measure-
ments will be taken with shoes off in the standing
position. Measurements will be taken twice during
two separate visits using the height scale (Seca 206)
with an accuracy of one millimeter. The average of
the two measurements will be recorded. If the second
measurement is greater than or less than the 1.5 %
standard deviation of the first measurement, a third
measurement will be made and the midpoint meas-
urement will be recorded. The infant’s height will be
measured by the infant’s recumbent length, using a
horizontal length scale (Seca 376), with an accuracy
of 1 mm. Blood pressure will be taken using a regu-
larly tested aneroid sphygmomanometer (Seca b10) in
a calm environment with suitable temperature. The
participant will be seated in an upright position and
asked to remove excess clothes that constrict arm
blood flow. After relaxing for 3–5 min, blood pres-
sure will be measured in the right arm, which will be
placed on a table and raised to the level of the heart,
with the back supported during the measurement.
The measurement will be repeated about five minutes
later, and the average of two measurements will be
recorded. Participants will be asked to avoid intense
activity, heavy meals, coffee, alcohol, stimulant drugs
or drinks, and tobacco for at least half an hour prior
to measuring blood pressure.
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Biospecimen collection procedures
Ten cubic centimeters of venous blood will be collected
from the ulnar vein and mixed with an appropriate pro-
portion of ethylenediaminetetraacetic acid (EDTA) anti-
coagulant. All blood samples will be analyzed in a single
laboratory at Arash Hospital. Samples will be tested a
maximum of four hours after sampling by an automated
hematology analyzer (Sysmex Corporation, Kobe, Japan).
Hematological indices in this study will include white
blood cell count (WBC), red blood cell count (RBC),
platelet count (Plt), hemoglobin (Hb), hematocrit
(HCT), mean corpuscular volume (MCV), mean corpus-
cular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), standard deviation and coeffi-
cient of variation of red cell distribution width (RCDW-
SD and RCDW-CV), platelet distribution width (PDW),
mean platelet volume (MPV), and platelet larger cell ra-
tios (PLCR). At the same time, the differential count of
white blood cells will be performed by peripheral blood
smear stained with Giemsa color. The following labora-
tory parameters will be collected between 24 and 28
weeks of gestation: Hepatitis B virus (HBV) antigen
(Ag), human immunodeficiency virus (HIV) antibody
(Ab), hepatitis C virus (HCV) Ab, blood group, RH,
indirect coombs, triglycerides (TG), total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, Hb A1C, fasting blood
sugar (FBS), blood urea nitrogen (BUN), creatinine,
urine culture, thyroid-stimulating hormone (TSH), 25
OH VitD3, and glucose tolerance test (GTT) 75 g or
glucose challenge test (GCT) 50 g following by GTT
100 g in the case of abnormal GCT. For insurance of the
accuracy of the results, the device will be calibrated by
the reference methods prior to testing. Also, to ensure
day-to-day consistency of the analytical process, a regu-
lar quality control program will be performed during the
tests. We will determine the serum glucose level with
the oxidase method using Hitachiauto analyzer model
7700 (Hitachi Medical, Tokyo, Japan). For GCT 50 g, a
blood sample will be taken one hour after the consump-
tion of a syrup containing 50 g of glucose. Participants
who have a GCT between 140 and 200 mg/dl will
undergo a 100 gram oral GTT. For GTT 75 g, after
measurement of FBS, participants will be asked to drink
a syrup containing 75 g of glucose. At one hour and two
hours after consumption of the syrup, serum glucose
levels will be measured again.
Physical activity
The International Physical Activity Questionnaire
(IPAQ) will be used to collect information on the
quantity and quality of physical activity. Participants
will record the amount of time spent on each activ-
ity level as the number of days in the last seven-day
period and average amount of time per day. Physical
activity quality will be listed as: vigorous (activities
that require intense physical exertion and cause the
participant to breathe much stronger than usual(,
moderate (activities that take moderate physical ef-
fort and make the participant breathe somewhat
harder than normal), walking (including at work and
at home, walking to move from one location to an-
other, and any other walk intended solely for recre-
ation, sport, exercise or recreation), and sitting
(including time spent at work, at home, while doing
course work and during leisure time) [15, 16]. This
physical activity information will be converted to
Metabolic Equivalent of Tasks (METs). The METs
or metabolic equivalent is a physiological measure
expressing the energy cost of physical activity and is
defined as the ratio of the metabolic rate in a given
physical activity to the baseline metabolic rate. One
MET shows the amount of energy consumed when
sitting quietly at rest and is equivalent to 3.5 ml/kg/
min of VO2 Max. [17].
Sleep Quality
We will assess sleep quality during the third visit (32
weeks ± 12 days) via the Pittsburgh sleep quality index–
19 items (PSQI-19), Epworth sleepiness scale (ESS), and
insomnia severity index (ISI). The PSQI-19 is a widely
used and well-validated19-itemself-rating questionnaire
that measures clinical and subjective sleep complaints in
adults during the previous month. PSQI-19 generates
seven component scores, including subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleeping medication,
and daytime dysfunction. The PSQI-19 provides a global
score ranging from no sleep difficulty to severe difficul-
ties. A cut-off value of five has been shown to have a
sensitivity of 89.6 % and a specificity of 86.5 % for the
diagnosis of poor sleep quality [18, 19]. The ESS is a
questionnaire that measures daytime sleepiness. The
scores range from 0 to 24, and a total score of over 10
indicates excessive day time sleepiness [20, 21]. The ISI
is a self-reportedseven-item questionnaire with scores
ranging from 0 to 28 as follows: no insomnia (0–7), sub-
threshold insomnia (8–14), moderate insomnia (15–21),
and severe insomnia (22–28)[22, 23].
Establishing the GA
Ultrasound scans for each participant will be performed
through diagnostic medical sonography by an ultrasound
technician five times during the pregnancy to monitor
fetal development, possible abnormalities, and the exact
GA. The initial ultrasound should occur between 6 and
12 weeks’ gestation. One sonographer will perform all
scans to reduce the risk of measurement errors. The
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expected date of delivery (EDD) will be calculated ac-
cording to Naegele’s rule, based on the first day of the
last menstrual period (LMP) [24]. If a participant does
not accurately recall the LMP or has irregular menstrual
periods, the GA and EDD will be calculated based on
the initial first trimester ultrasound. If the difference in
GA between the patient’s LMP and initial ultrasound is
more than five days in the first trimester, the GA and
EDD will be calculated based on the initial ultrasound.
Providing routine antenatal care for women
For all first time pregnant women with no complica-
tions, seven visits will be conducted. After the first visit
at 6 to 10 weeks of pregnancy, subsequent visits will
happen between weeks 16–20, 24–30, 31–34, 35–37, 38,
39 and 40. In the first visit, the following variables will
be measured: menstrual status, gestational age and ap-
proximate date of delivery, history of underlying disease,
previous history of genetic disease, history of high-risk
behaviors in couples, history of psychiatric disorder and
of intimate partner violence, drug use and drug sensitiv-
ity. Examinations performed during each visit will in-
clude monitoring vital signs, measuring weight, uterine
height and determining gestational age, listening to the
fetal heartbeat, recording fetal movements, and review-
ing maternal complaints. During the first visit, the fol-
lowing tests will be performed: HBsAg, TSH, VDRL,
HIV, CBC, BG, U/A, U/C, BUN, Cr, and FBS. An indir-
ect Coombs assay may be used to determine if there are
antibodies to factor Rh in the woman’s blood. Labora-
tory tests will be repeated at 24 to 28 weeks of preg-
nancy (preferably at 28 weeks) as follows: CBC, FBS,U/A
and a second indirect Coombs assay. Targeted ultra-
sound will be performed at 16 to 18 weeks of gestation
to assess placental migration and fetal abnormalities.
Ultrasound will be performed at 31 to 34 weeks of gesta-
tion to assess the growth status of the fetus, placenta
and amniotic fluid.
Primary outcome measures
Adverse outcomes associated with pregnancy will be di-
agnosed and confirmed through examination by a peri-
natologist and laboratory assessments. The pregnancy
outcomes considered in this study are as follows: spon-
taneous abortion, ectopic pregnancy, preterm pre-labor
rupture of membranes (PPROM), type of delivery (vagi-
nal, operative vaginal, or cesarean), gestational age at de-
livery, gestational hypertension, preeclampsia, HELLP
(hemolysis, elevated liver enzyme levels, and low platelet
levels) syndrome, preterm labor, gestational diabetes
mellitus (GDM), anemia, acute fatty liver, polyhydram-
nios, oligohydramnios, placenta previa, placenta accreta,
retained placenta, postpartum hemorrhage (PPH), post-
partum infection and any other complication. Fetal
measurements will include height, weight, and head cir-
cumference. Adverse fetal outcomes will include birth
trauma, shoulder dystocia, intrauterine growth restric-
tion (IUGR), intrauterine fetal death (IUFD), meconium
aspiration syndrome, fetal distress syndrome, transient
tachypnea of the newborn (TTN), apnea, neonatal inten-
sive care unit (NICU) admission, macrosomia, low birth
weight (LBW), prematurity, intraventricular hemorrhage
(IVH) and any other complication.
Power calculation and sample size
We calculated the sample size by considering a 5 %
probability of detecting at least one adverse outcome in
non-exposed pregnant women and with a prespecified
RR = 2 as a measure of association. A total sample of
475 pregnant women per group including a 10 % drop-
out factor is assumed to provide 80 % power to detect a
difference in the incidence of adverse event between the
exposed and non-exposed groups; and a two-sided test
having a type I error of 0.05.
Statistical analysis
Data processing and statistical analysis will be performed
using the Stata statistical package version 16 (Stata Corp
LP, College Station, TX, USA). Analysis of baseline data
will be conducted to describe the socio-demographics,
nutritional status, and birth characteristics of pregnant
women. The normality of data will be checked for ex-
treme values and outliers using normality plots (histo-
gram and Q-Q) and visual inspection. Data will be
presented as mean scores ± SD for continuous data and
as percentages for categorical data. Normally distributed
data will be presented as means ± SD; non-normally dis-
tributed data will be expressed as medians (25th per-
centile, 75th percentile). Data will be analyzed by linear
regression models, including analysis of variance
(ANOVA), analysis of covariance (ANCOVA), multiple
linear regression analysis and linear mixed-models. The
level of significance will be set at p < 0.05.
Discussion
The importance of perinatal status and its role in ma-
ternal and child health is indisputable. Strategies to
promote nutritional interventions in community and
facility settings have shown promising benefits for
women and child health; however, evidence for the
specific effects of micro-nutrients on pregnancy and
neonatal outcomes is scarce [25]. The findings of a
comprehensive review have highlighted ten evidence-
based nutrition interventions to address nutrition and
micronutrient deficiencies in women and children.
The results emphasized that the current total number
of deaths in children under five can be reduced by
15 % if pregnant women can access ten evidence-
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based nutritional interventions at 90 % coverage. The
results further concluded that continued investments
in nutrition-specific interventions can prevent mater-
nal and child malnutrition and micronutrient deficien-
cies, alongside improving pregnancy outcomes. Thus,
there is insufficient evidence about the interaction be-
tween various micro-nutrients and pregnancy out-
comes [26]. A clear need exists to introduce
promising evidence-based interventions during the
preconception and prenatal period in countries highly
burdened by poor nutrition and young maternal age
of first pregnancies.
The authors of the aforementioned review proposed
that future studies should focus on these aspects en-
suring consistency in measurement and reporting of
outcomes. With the MATCH study, we aim to evalu-
ate the effect of nutrition, sleep quality, and lifestyle
during antenatal and postpartum periods on mothers’
and newborns’ well-being. The most important
strength of this study is the multifactorial approach
to perinatal health combined with a longitudinal de-
sign with measurements during all trimesters of preg-
nancy. Another strength of the current study is the
comprehensive assessment of risk factors related to
adverse pregnancy outcomes. These factors include
nutritional pattern, physical activity, sleep distur-
bances, medical history, previous pregnancy history,
lifestyle, and socioeconomic status. In this study, data
will be collected by trained interviewers, which con-
siderably reduces and minimizes measurement error.
Furthermore, due to of the large sample size, risk fac-
tors for rare pregnancy outcomes can be identified.
The main limitation of the current study, like other
cohort studies, is loss to follow up. However, through
use of social networks, educational pamphlets, and
continuous communication, we aim to minimize the
attrition rate. Further, the site of this study is a spe-
cialized gynecological hospital, which may introduce
selection bias which could reduce the generalizability
of the study findings. However, as Arash Hospital is
the largest maternity hospital in eastern Tehran, it
treats all pregnant women from the province of
Tehran and across the country of Iran, rendering the
patient population diverse. In order to maintain
consistency in data collection from a large patient
population, this study was designed as a single-center
study to preserve internal validity [27].
The MATCH prospective cohort study, which is
representative of pregnant women in an Iranian urban
setting, will expand our current knowledge about the
casual effects of life style factors on prenatal and neo-
natal outcomes. The findings will promote evidence-
based medicine, inform decision makers about the
health and well-being of pregnant women and
neonates, improve the counselling of future pregnant
women and guide clinician management.
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